AbbVie Completes Acquisition of Pharmacyclics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- Wall Street ends down as US-Iran peace optimism fades
- eToro to acquire TradeZero for up to $231M to expand in US
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Morgan Stanley Resumes Abbvie (ABBV) at Equalweight
May 28, 2015 7:58 AM EDTMorgan Stanley resumed coverage on Abbvie (NYSE: ABBV) with an Equalweight rating.
For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.
Shares of Abbvie closed at $67.38 yesterday.
... MoreCowen Raises Price Target on AbbVie (ABBV) Due to Enhanced Visability
May 27, 2015 11:39 AM EDTCowen maintains an Outperform rating on Abbvie (NYSE: ABBV), and raised the price target to $72.00 (from $70.00) to show for enhanced viability. Analyst Steve Scala says that ABBV has consistently delivered EPS upside, and it is possible that forecasts move up over time.... More
AbbVie (ABBV) Enters $5B Accelerated Common Stock Buyback Agreement
May 27, 2015 6:09 AM EDTAbbVie (NYSE: ABBV) disclosed the following on Wednesday:
On May 26, 2015, AbbVie Inc. (AbbVie) entered into an accelerated share repurchase agreement (the agreement) with Morgan Stanley & Co. LLC (Morgan Stanley) to repurchase $5.0 billion (the prepayment amount) of AbbVies common stock. Morgan Stanley is expected to make an initial delivery of approximately 68 million shares of... More
AbbVie (ABBV) Announces Completion of Pharmacyclics Acquisition
May 26, 2015 8:33 AM EDTAbbVie (NYSE: ABBV) has completed the acquisition of Pharmacyclics, Inc. (Nasdaq: PCYC) enhancing AbbVie's scientific and commercial presence in oncology. Pharmacyclics is a leader in the hematological oncology market with Imbruvica® (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 billion global market.
"The companies' shared expertise, combined with AbbVie's broad late-stage oncology pipeline, has the potential to transform the cancer treatment landscape for hematological malignancies and improve patient outcomes and quality of life," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie.... More
